BACKGROUND: Proficiency testing (PT), or external quality assessment (EQA), is intended to verify on a recurring basis that laboratory results conform to expectations for the quality required for patient care. CONTENT: Key factors for interpreting PT/EQA results are knowledge of the commutability of the samples used and the process used for target value assignment. A commutable PT/EQA sample demonstrates the same numeric relationship between different measurement procedures as that expected for patients' samples. Noncommutable PT/EQA samples frequently have a matrix-related bias of unknown magnitude that limits interpretation of results. PT/EQA results for commutable samples can be used to assess accuracy against a reference measurement procedure or a designated comparison method. In addition, the agreement of the results between different measurement procedures for commutable samples reflects that which would be seen for patients' samples. PT/EQA results for noncommutable samples must be compared to a peer group mean/median of results from participants who use measurement procedures that are expected to have the same or very similar matrix-related bias. Peer group evaluation is used to asses whether a laboratory is using a measurement procedure in conformance to the manufacturer's specifications and/or in conformance to other laboratories using the same technology. A noncommutable PT/EQA sample does not give meaningful information about the relationship of results for patients' samples between different measurement procedures. SUMMARY: PT/EQA provides substantial value to the practice of laboratory medicine by assessing the performance of individual laboratories and, when commutable samples are used, the status of standardization or harmonization among different measurement procedures.
BACKGROUND: Proficiency testing (PT), or external quality assessment (EQA), is intended to verify on a recurring basis that laboratory results conform to expectations for the quality required for patient care. CONTENT: Key factors for interpreting PT/EQA results are knowledge of the commutability of the samples used and the process used for target value assignment. A commutable PT/EQA sample demonstrates the same numeric relationship between different measurement procedures as that expected for patients' samples. Noncommutable PT/EQA samples frequently have a matrix-related bias of unknown magnitude that limits interpretation of results. PT/EQA results for commutable samples can be used to assess accuracy against a reference measurement procedure or a designated comparison method. In addition, the agreement of the results between different measurement procedures for commutable samples reflects that which would be seen for patients' samples. PT/EQA results for noncommutable samples must be compared to a peer group mean/median of results from participants who use measurement procedures that are expected to have the same or very similar matrix-related bias. Peer group evaluation is used to asses whether a laboratory is using a measurement procedure in conformance to the manufacturer's specifications and/or in conformance to other laboratories using the same technology. A noncommutable PT/EQA sample does not give meaningful information about the relationship of results for patients' samples between different measurement procedures. SUMMARY: PT/EQA provides substantial value to the practice of laboratory medicine by assessing the performance of individual laboratories and, when commutable samples are used, the status of standardization or harmonization among different measurement procedures.
Authors: Hedwig C M Stepman; Ulla Tiikkainen; Dietmar Stöckl; Hubert W Vesper; Selvin H Edwards; Harri Laitinen; Jonna Pelanti; Linda M Thienpont Journal: Clin Chem Date: 2014-03-31 Impact factor: 8.327
Authors: Elisabet González-Lao; Jorge Díaz-Garzón; Zoraida Corte; Carmen Ricós; Carmen Perich; Virtudes Álvarez; Margarita Simón; Joana Minchinela; José Vicente García-Lario; Beatriz Boned; Carmen Biosca; Fernando Cava; Pilar Fernández-Fernández; Pilar Fernández-Calle Journal: Ann Transl Med Date: 2017-03
Authors: Amélie Gaignaux; Garry Ashton; Domenico Coppola; Yvonne De Souza; Annemieke De Wilde; James Eliason; William Grizzle; Fiorella Guadagni; Elaine Gunter; Iren Koppandi; Katheryn Shea; Tim Shi; Julie A Stein; Mark E Sobel; Gunnel Tybring; Gert Van den Eynden; Fay Betsou Journal: Biopreserv Biobank Date: 2016-05-19 Impact factor: 2.300
Authors: Robin DiFrancesco; Susan L Rosenkranz; Charlene R Taylor; Poonam G Pande; Suzanne M Siminski; Richard W Jenny; Gene D Morse Journal: Ther Drug Monit Date: 2013-10 Impact factor: 3.681
Authors: Richard W Browne; Susan L Rosenkranz; Yan Wang; Charlene R Taylor; Robin DiFrancesco; Gene D Morse Journal: Ther Drug Monit Date: 2019-08 Impact factor: 3.681
Authors: Ekaterina M Mineva; Maya R Sternberg; Christine M Pfeiffer; Shahzad S Momin; Khin L Maw; Rosemary L Schleicher Journal: Clin Chim Acta Date: 2018-10-04 Impact factor: 3.786